These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
15. The editor's roundtable: the JUPITER trial--initial results and clinical implications. Ridker PM; Friedewald VE; Davidson MH; Willerson JT; Roberts WC Am J Cardiol; 2009 May; 103(10):1417-25. PubMed ID: 19427439 [No Abstract] [Full Text] [Related]
16. Balancing risks and benefits of cyclooxygenase-2 selective nonsteroidal anti-inflammatory drugs. Scheiman JM Gastroenterol Clin North Am; 2009 Jun; 38(2):305-14. PubMed ID: 19446260 [TBL] [Abstract][Full Text] [Related]
17. The editor's roundtable: prehypertension. Roberts WC; Bakris GL; Black HR; Sica DA; Sulkes DJ Am J Cardiol; 2009 Oct; 104(8):1105-15. PubMed ID: 19801033 [No Abstract] [Full Text] [Related]
18. Cardiovascular safety of the cyclooxygenase-2 selective inhibitors parecoxib and valdecoxib in the postoperative setting: an analysis of integrated data. Schug SA; Joshi GP; Camu F; Pan S; Cheung R Anesth Analg; 2009 Jan; 108(1):299-307. PubMed ID: 19095866 [TBL] [Abstract][Full Text] [Related]
19. Cardiovascular risk of cyclooxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs. Hermann M; Ruschitzka F Ann Med; 2007; 39(1):18-27. PubMed ID: 17364448 [TBL] [Abstract][Full Text] [Related]
20. Periodontal infections and cardiovascular disease: is it a mere association? Humagain M; Nayak DG; Uppoor AS Kathmandu Univ Med J (KUMJ); 2006; 4(3):379-82. PubMed ID: 18603938 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]